Modifies provisions relating to the ordering and administration of ketamine for mental health purposes
Summary
HB 1043 repeals and replaces Missouri’s existing controlled-substances statute section 195.070 to add specific rules for ketamine used for mental health purposes, while leaving the broader framework for prescribing and dispensing controlled substances largely intact. The bill continues to authorize physicians, podiatrists, dentists, certain optometrists, assistant physicians, physician assistants, advanced practice registered nurses with controlled-substance authority, and veterinarians to prescribe or administer controlled substances within their existing scopes of practice and subject to current limits.
The new provisions focus on intravenous ketamine hydrochloride treatment for mental health care. They prohibit a physician from delegating the authority to order ketamine for mental health purposes to another individual, require a physician to be on site and immediately available if a certified registered nurse anesthetist administers ketamine, and require a documented physician diagnosis and treatment plan before IV ketamine can be given for mental health purposes. The bill also retains existing restrictions on handling unused controlled substances, self-prescribing, and limits on certain Schedule II and Schedule III prescriptions.
Impact
The bill would amend Missouri’s controlled-substances law by creating a specific statutory framework for ketamine hydrochloride when used for mental health treatment. It would impose physician oversight requirements, limit delegation, and require documentation before administration, thereby affecting physicians, certified registered nurse anesthetists, and facilities offering ketamine-based mental health treatment. It does not broadly legalize or expand ketamine use; instead, it regulates how it may be ordered and administered in this context.
Sentiment
Based on the bill text and available context, the measure appears to be framed as a patient-safety and oversight bill rather than a controversial expansion of drug access. There are no recorded committee transcripts or votes in the provided material, so there is no direct evidence of support or opposition from lawmakers. The structure of the bill suggests an intent to clarify professional responsibilities and tighten controls around a specialized mental health treatment.
Contention
The main point of potential contention is the degree of physician control required for ketamine treatment. Supporters would likely view the bill as ensuring medical oversight, documented diagnosis, and safer administration standards, while critics could argue that the on-site physician requirement and ban on delegation may limit access to treatment or create operational burdens for clinics. Another possible issue is the restriction on who may administer ketamine and under what supervision, especially for practices that rely on nurse anesthetists or collaborative care models.